MDX-240(MDX-240) - 药物靶点：CD64 x gp41_专利_临床

概要

基本信息

药物类型

双特异性抗体

别名

Anti-gp41-anti-Fc monoclonal antibody

靶点

CD64 x gp41

作用方式

拮抗剂、抑制剂

作用机制

CD64拮抗剂(高亲和力免疫球蛋白γFc受体I拮抗剂)、gp41抑制剂(跨膜糖蛋白gp41抑制剂)

治疗领域

免疫系统疾病感染泌尿生殖系统疾病

在研适应症-

非在研适应症

HIV感染

原研机构

Medarex, Inc.

在研机构-

非在研机构

Medarex, Inc.

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 MDX-240 相关的临床结果

登录后查看更多信息

100 项与 MDX-240 相关的转化医学

登录后查看更多信息

100 项与 MDX-240 相关的专利（医药）

登录后查看更多信息

1

项与 MDX-240 相关的文献（医药）

1995-12-01·Journal of Hematotherapy

Functional Consequences of Macrophage Infection by Human Immunodeficiency Virus: Bispecific Antibody Targeting of HIV-1-Infected Cells to FcγRI Expressing Effector Cells

Article

作者: Le Naour, R ; Raoul, H ; Cheret, A ; Dormont, D ; Le Grand, R ; Vaslin, B ; Romet-Lemonne, J L ; Mabondzo, A ; Benveniste, O

Human monocytes/macrophages play a major role in pathogenesis of human immunodeficiency virus (HIV) infection. These cells have been suspected of acting as a reservoir for the virus and are important in viral dissemination and persistence in infected individual. Furthermore, several biologic and clinical features indicate that monocytes/macrophages from HIV-1-seropositive patients have characteristics of an activation status, including the ability to secrete high levels of cytokines. Dysregulation of the cytokine network may influence the level and the consequences of viral replication in infected monocytes/macrophages. Therefore, the development of virus-specific agents that may interfere with viral replication could help to slow down the fatal course of HIV infection. In this article, we try to further quantify the early and late kinetic patterns of the cytokine network during HIV-1 macrophage infection and report the biologic effects of virus-specific bispecific antibody (MDX-240) in HIV-1 macrophage infection.

100 项与 MDX-240 相关的药物交易

登录后查看更多信息